From: The role of radiotherapy in multimodal treatment of pancreatic carcinoma
Trial (patients) | Chemotherapy* | Radiotherapy (Gray) | Median survival (months) | p-value |
---|---|---|---|---|
Johnson[59] (129) | Lithium Gamonelate | - | 5.4 | n.a. |
Maisey[56] (44/46) |
5/FU PVI 5-FU/MMC | - |
32% 1 year 43% 1 year | n.a. |
Louvet[60] (47/50) |
Gem Gem/Ox |
- -$ |
10.3 10.3 | p = n.s. |
Rocha Lima[61] (24/27) |
Gem Gem/Iri |
- -$ |
11.7 9.8 | p = n.s. |
Van Cutsem[62] (80/82) |
Gem Gem/tipifarnib | - |
8.7 11 | p = n.s. |
GITSG 1985[77] (25/83/86) |
- 5-FU 5-FU |
60 40 60 |
5.2 9.6 9.2 | p < 0.01 |
GITSG 1988[50] (24/24) |
SMF
SMF |
54 - |
6.5 5.1 | p < 0.02 |
Klaassen[52] (44/47) |
5-FU
5-FU |
40 - |
8.3 8.2 | n.a. |
Chauffert[53] (59/60) |
5-FU(PVI)/Cis+Gem Gem |
60 - |
8.0 14.5 | p = 0.03 |
Loehrer[55] (36/38) |
Gem+ Gem Gem |
50.4 - |
11.0 9.2 | p = 0.034 |
Crane[66] (53/61) |
Gem
5-FU(PVI) | 30 (10#) |
11 9 | p = n.s. |
Li[78] (18/16) |
Gem
5-FU | 50.4 |
14.5 6.7 | p = 0.027 |
Ishii[63] (20) | 5-FU(PVI) | 50.4 | 10.3 | n.a. |
McGinn[65] (37) | Gem | 24-42 | 11.6 | n.a. |
Shinchi[47] (16/15) |
5-FU(PVI) Supportive care |
50.4 - |
13.2 6.4 | n.a. |
Brunner[67] (40/42) |
Gem/Cis+ Gem Gem/Cis |
55.8 55.8 | 13 8 | p < 0.0001 |
Huguet[24] (72/56) |
5-FU(PVI)+ as below FolFuGem, GemOx |
55 - |
15 11.7 | p = 0.0009 |
Kachnic[64] (23) | 5-FU+ Gem | 50.4 | 13 | n.a. |